Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This is a randomised phase 2 study of paclitaxel with or without GSK1120212 or pazopanib in advanced wt BRAF melanoma


To evaluate, in a randomised phase 2 study, the efficacy of paclitaxel with or without the MEK inhibitor GSK1120212 (of which the most tolerable dose has been confirmed) or pazopanib in wild type BRAF metastatic melanoma, stratifying for NRAS mutation status.




  • Progression free survival


  • Objective response rate.
  • Progression free survival at 6 months
  • Safety of the GSK1120212/paclitaxel and pazopanib/paclitaxel combination
  • Overall survival.

Trial Publications

The primary results publication can be found here.

A further results publication can be found here